TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01480908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography at rest
Description: Dimensions of all 4 chambers, inspiratory collapse, and gradient over the tricuspid valve is measured. Tricuspid Annulus Plane Systolic Excursion(TAPSE) and Tricuspid Annular peak Systolic Motion(TASM) is measured as well.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography at rest
Description: Dimensions of all 4 chambers, inspiratory collapse, and gradient over the tricuspid valve is measured. Tricuspid Annulus Plane Systolic Excursion(TAPSE) and Tricuspid Annular peak Systolic Motion(TASM) is measured as well.
Study: NCT01480908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography at rest
Description: Dimensions of all 4 chambers, inspiratory collapse, and gradient over the tricuspid valve is measured. Tricuspid Annulus Plane Systolic Excursion(TAPSE) and Tricuspid Annular peak Systolic Motion(TASM) is measured as well.
Study: NCT01387087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study: NCT01480908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography during exercise
Description: TASM is measured during exercise along with pulse measurements to evaluate the force-frequency-relation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography during exercise
Description: TASM is measured during exercise along with pulse measurements to evaluate the force-frequency-relation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography during exercise
Description: TASM is measured during exercise along with pulse measurements to evaluate the force-frequency-relation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI at rest
Description: Dimensions of all 4 chambers are measured at end-systole and end-diastole. Blood flow measurements through the aortic and the pulmonary valve are made as well. No use of contrast.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI at rest
Description: Dimensions of all 4 chambers are measured at end-systole and end-diastole. Blood flow measurements through the aortic and the pulmonary valve are made as well. No use of contrast.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI at rest
Description: Dimensions of all 4 chambers are measured at end-systole and end-diastole. Blood flow measurements through the aortic and the pulmonary valve are made as well. No use of contrast.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise testing
Description: Maximal oxygen consumption is measured during on a bicycle. Prior to the test a spirometry is performed to rull out potential differences in pulmonary function between the cohorts. During the test pulse, blood pressure, saturation, and EKG are monitored. Ventilatory volume, oxygen consumption and carbon dioxide excretion are measured. Anaerobic threshold is calculated at the end of the test.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise testing
Description: Maximal oxygen consumption is measured during on a bicycle. Prior to the test a spirometry is performed to rull out potential differences in pulmonary function between the cohorts. During the test pulse, blood pressure, saturation, and EKG are monitored. Ventilatory volume, oxygen consumption and carbon dioxide excretion are measured. Anaerobic threshold is calculated at the end of the test.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise testing
Description: Maximal oxygen consumption is measured during on a bicycle. Prior to the test a spirometry is performed to rull out potential differences in pulmonary function between the cohorts. During the test pulse, blood pressure, saturation, and EKG are monitored. Ventilatory volume, oxygen consumption and carbon dioxide excretion are measured. Anaerobic threshold is calculated at the end of the test.
Study: NCT01528631

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: D-Fagomine
Description: 30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: D-Fagomine
Description: 0 mg (control) blended with 50 grams of sucrose in 200 ml of water.
Study: NCT02965469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathe2Relax
Description: The app teaches diaphragmatic breathing and has audiovisual coaching
Study: NCT03941171

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PAO
Description: PAO will be performed as the trans-sartorial approach or the anterior pelvic approach.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care after PAO
Description: Patients commence post-operative rehabilitation as usual and follow the rehabilitation program guided by a physiotherapist specialized in hip problems until 4 months after the operation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRT
Description: 4 months of partly supervised progressive resistance training 2 times per week. After these 4 months (16 weeks), patients receive a free membership to a fitness center near their home address and are encouraged to train on their own 2 times per week until 12 months follow-up with one supervised session per month. The PRT program involves 10-min of warm up followed by 50-min of bilateral resistance exercises including sets of squats, hip extension, hip flexion, and hip abduction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRT
Description: 4 months of partly supervised progressive resistance training 2 times per week. After these 4 months (16 weeks), patients receive a free membership to a fitness center near their home address and are encouraged to train on their own 2 times per week until 12 months follow-up with one supervised session per month. The PRT program involves 10-min of warm up followed by 50-min of bilateral resistance exercises including sets of squats, hip extension, hip flexion, and hip abduction.
Study: NCT02583178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aegis Sierra Ligation System
Description: The SLS is a series of devices designed for epicardial ligation of the left atrial appendage through a minimally invasive transcatheter approach.
Study: NCT00366678

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine
Description: Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentavac
Description: The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentavac
Description: The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
Study: NCT02007369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp
Description: Intervention arm with relapse prevention intervention in the social group via the social networking service WhatsApp and the duration of the intervention will be 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facebook
Description: Another intervention arm with the same intervention content, but the platform for the participants to share and receive quitting advice is Facebook and the duration of the intervention will be 8 weeks.
Study: NCT03151967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus crispatus CTV-05
Description: vaginal applicator with medium containing drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vaginal applicator with medium containing no drug
Study: NCT00470119

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: behavioral dietary intervention
Description: A group based modification of the DPP and LookAHEAD lifestyle programs with a goal of 10% weight loss

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: behavioral dietary intervention
Description: A group based modification of the DPP and LookAHEAD lifestyle programs with a goal of 10% weight loss

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise intervention
Description: Facility based and home-based exercise designed to increase moderate-to-vigorous aerobic activity in participants to 45 mins/day 5 days/week

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise intervention
Description: Facility based and home-based exercise designed to increase moderate-to-vigorous aerobic activity in participants to 45 mins/day 5 days/week
Study: NCT03822936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Description: Preoperative chemotherapy, carbon ion therapy, surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Description: Preoperative chemotherapy, carbon ion therapy, surgery
Study: NCT01190098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Subjects randomized to lacosamide according to the following schedule:~Treatment Phase Week Dose Week 1 LCM 50 mg bid Week 2 LCM 100 mg bid Week 3 LCM 150 mg bid Week 4 LCM 200 mg bid
Study: NCT01190098

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be packaged identically to experimental drug and titrated according to the same schedule.
Study: NCT02768220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: empagliflozin
Description: Test to see how 30 days of jardiance changes serum and urinary advanced glycation end product levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin
Description: Test to see how 30 days of tradjenta changes serum and urinary advanced glycation end product levels
Study: NCT03798522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral ultrasound guided erector spinae plane block
Description: ESPB on both sides at T7 before GA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: in nalbuphine for analgesia after GA
Study: NCT03125629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FDG
Description: Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FDG
Description: Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-DOTA-TATE
Description: Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-DOTA-TATE
Description: Radiolabel for positron emission tomography / computed tomography (PET/CT) and computed tomography (PET/CT) imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography / Computed Tomography (PET/CT) Scan
Description: Scan using a regular medical care (IDE-exempt) Discovery 600 / 690 PET/CT scanner.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography / Computed Tomography (PET/CT) Scan
Description: Scan using a regular medical care (IDE-exempt) Discovery 600 / 690 PET/CT scanner.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan
Description: Scan using a NOVEL GE PET/MRI scanner.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan
Description: Scan using a NOVEL GE PET/MRI scanner.
Study: NCT01283711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: apollo device
Description: RF treatments for wrinkles and rhytides reduction
Study: NCT03066635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 25 IU
Description: injection with 25 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A 12.5 IU
Description: injection with 12.5 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
Study: NCT03829033

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy with either photons or protons.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy with either photons or protons.
Study: NCT01476345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2963016
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lantus
Description: Administered subcutaneously
Study: NCT03552679

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography
Study: NCT00747422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera™ System
Description: ultrasound treatment
Study: NCT02337426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT02537067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHONDRON
Description: 1. Harvesting of ankle or knee cartilage~2. The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
Study: NCT03918395

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: A placebo beverage will be consumed both post-exercise and pre-bed

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein-polyphenol beverage
Description: A protein-polyphenol beverage will be consumed both post-exercise and pre-bed
Study: NCT03707522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth mindset
Description: 10 minute interactive article describing neuroplasticity
Study: NCT01387087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT03707522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growth mindset
Description: 10 minute interactive article describing neuroplasticity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modifiable risk factor (MRF) information
Description: 10 minute interactive article describing modifiable risk factors for depression and anxiety

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modifiable risk factor (MRF) information
Description: 10 minute interactive article describing modifiable risk factors for depression and anxiety
Study: NCT02610062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGS67E
Description: Intravenous (IV) infusion
Study: NCT03447769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: 200 mg of canakinumab administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Canakinumab solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously on day 1 of every 21-day cycle for 18 cycles. Placebo solution for injection was provided by Novartis as ready-to-use pre-filled syringes to be administered by study personnel.
Study: NCT04040985

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Knee Arthroplasty using LEGION™ Total Knee System
Description: Primary Total Knee Arthroscopy using LEGION™ Total Knee System
Study: NCT03707522

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 10 minute interactive article describing activity scheduling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: 10 minute interactive article describing activity scheduling
Study: NCT01387087

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01321749

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
Study: NCT03481673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE for Asthma
Description: The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression.
Study: NCT03707522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: 10 minute interactive article describing activity scheduling
Study: NCT04445129

Intervention type: DEVICE
Intervention: Portable EEG Device
Description: Portable EEG device is lightweight and designed for nighttime wear.

Intervention type: DEVICE
Intervention: Portable EEG Device
Description: Portable EEG device is lightweight and designed for nighttime wear.

Intervention type: DEVICE
Intervention: Portable ECG Device
Description: Portable ECG device is waterproof and will be adhered to the chest of the participant.

Intervention type: DEVICE
Intervention: Portable ECG Device
Description: Portable ECG device is waterproof and will be adhered to the chest of the participant.

Intervention type: DEVICE
Intervention: Accelerometry
Description: Portable accelerometry device is noninvasive and will capture data on participant activity level, including intensity of movement, rest, and sleep.

Intervention type: DEVICE
Intervention: Accelerometry
Description: Portable accelerometry device is noninvasive and will capture data on participant activity level, including intensity of movement, rest, and sleep.
Study: NCT01660490

Intervention type: PROCEDURE
Intervention: ORIF
Description: Open reduction internal fixation of the proximal femur
Study: NCT02535676

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The device will produce a direct current of 2 mA from one electrode to the other. In active stimulation, the device will be turned on for 20 min and in sham stimulation the device will be turned in 2 mA for one minute and will be automatically turned off the remaining 19 minutes. The sham or active mode is chosen by a numeric code.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The device will produce a direct current of 2 mA from one electrode to the other. In active stimulation, the device will be turned on for 20 min and in sham stimulation the device will be turned in 2 mA for one minute and will be automatically turned off the remaining 19 minutes. The sham or active mode is chosen by a numeric code.
Study: NCT01900379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: This device consists in a nasal continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/CPAP patients group.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham CPAP treatment
Description: This device consists in a sham continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/sham CPAP patients group.
Study: NCT00990028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 20 mg oral, for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg vehicle
Study: NCT03986164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guided surgery with bovine spongious bone substitute
Description: A minimally traumatic extraction will be performed aiming at the preservation of tissue integrity. After this step, milling will be performed using a sequence of guides and cutters recommended by the Raptor Implacil / Bioparts (Implacil De Bortoli) system manufacturer for implant installation (Cone Morse 3.5mm from 11-13mm Implacil De Bortoli) in computer-guided surgeries.~In the spaces between the implant and the buccal bone plate will be filled with xenogene biomaterial (Geistlich Bio-Oss 0.25-1mm). Immediately after implant installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm - Implacil De Bortoli) will be placed.~If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgery with bovine spongious bone substitute
Description: The sequence of cutters recommended by the manufacturer for this type of surgery and installation of the same type of implant (Cone Morse due cone 3.5mm) will be adopted. The perforations of the collar for future insertion of the implants will be performed aiming the installation of the implants with its platform installed with sub-crestal position. The implant should be installed along the palatine wall to obtain primary stability, at the center of the mesio-distal width predetermined by the final restoration, with a minimum distance of 2 mm from the adjacent tooth, and 3 mm from the free gingival margin, becoming slightly palatinate (Kan et al, 2018). Immediately after installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm) will be placed. If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days.